A Diagnostics & Imaging Week

Correlagen Diagnostics (Cambridge, Massachusetts) and Children’s Hospital Boston (Boston) reported the signing of a collaboration agreement intended to accelerate the adoption of clinically useful gene testing in patient care.

Correlagen will conduct research with staff at Children’s that is focused on the determination of the clinical validity of genetic testing to diagnose certain conditions and on the discovery of correlations between genetic variation and disease phenotypes.

The company also will develop and provide DNA-sequence assays to Children’s investigators for research purposes. Correlagen has the right to commercialize diagnostic testing that arises from certain collaborative research programs.

The collaboration will leverage Correlagen’s expertise in high-throughput DNA sequencing and the expertise of Children’s faculty members in the genes involved in certain disease areas to enable the translation of research into clinical diagnostic tests, the parties said.

DE-ID Data Corp. (Philadelphia) reported that the National Cancer Institute (NCI; Bethesda, Maryland) has licensed DE-ID software to be used as a de-identification component of some of the software applications developed in the Tissue Banks and Pathology workspace of the NCI-sponsored Cancer Biomedical Informatics Grid (caBIG).

The NCI will use DE-ID internally and sublicense the software to 16 NCI-designated cancer centers participating in caBIG across the U.S. as part of a program to advance the development of the caBIG network while considering longer-term, strategic options. The NCI license is for one year with the option to renew.

caBIG is a collaborative effort led by the NCI to create an interoperable information infrastructure linking teams of cancer researchers together in a worldwide web of cancer research.

“DE-ID plays a critical role in the development of multi-institution data sharing systems, serving as a HIPAA-compliance and security filter for personal health information in medical records and reports,” said Steven Merahn, MD, chief medical officer at DE-ID. “DE-ID saves time, reduces risk and increases productivity over manual de-identification or any pattern recognition or statistical software.”

DE-ID develops technology-based solutions to patient privacy issues for data mining, clinical research, and clinical trial recruitment.

In other grants/contracts news:

• Acacia Research (Newport Beach, California) said that its CombiMatrix (Mukilteo, Washington) group has entered into a global distribution agreement with VWR International (VWR; West Chester, Pennsylvania) to distribute CustomArrays and CatalogArrays for CombiMatrix. VWR’s sales and marketing organization presently serves more than 250,000 customers with worldwide sales of $3 billion.

CombiMatrix’s CustomArray platform consists of DNA probes built on semiconductor chips using the company’s technology and methods. Two classes of products are derived from the CustomArray platform: CustomArrays, with user-defined DNA content, and CatalogArrays, with DNA content pre-designed by CombiMatrix.

Those two classes cover the entire spectrum of customizability and convenience, the company said. Customers can define their own content, use pre-designed content, or use pre-designed content as a starting point and add or modify as they wish. Examples of CatalogArrays include those for cancer, cholesterol metabolism, toxicology, inflammation, oxidative stress, and HIV, among many others.

• GE Healthcare (Waukesha, Wisconsin) reported that Upper Valley Medical Center (Troy, Ohio), a non-profit 139-bed community hospital, has purchased GE’s Centricity Enterprise PACS for its main facility and four outpatient sites.

GE will install a full suite of imaging storage technologies, which is comprised of radiology and cardiology PACS (picture archiving and communications system) and Centricity CR, which scans image plates, digitizes the data and automatically transmits the image to the processing workstation for editing and storing in the PACS.

GE’s system will be integrated with the facility’s current hospital information system and will have integration with GE’s Muse cardiology information system.

In other GE Healthcare news, Albany Molecular Research (Albany, New York) reported the renewal of a manufacturing agreement with the company. AMRI will supply a raw material for use in GE Healthcare’s diagnostic imaging agents. The work will be conducted at Organichem (Rensselaer, New York), AMRI’s large-scale manufacturing subsidiary. The original agreement, which was set to expire in 2007, has been renewed until December 2010. The renewal also calls for AMRI to manufacture increased quantities of the raw material. Financial terms were not disclosed.

• Nihon Kohden (Tokyo), a global manufacturer of medical electronic equipment and the leading provider of cardiology equipment in Japan and China, and Inovise Medical (Portland, Oregon), a privately held cardiac diagnostic company, reported the two companies have signed a multi-year agreement to integrate Inovise Medical’s Audiocor heart sounds detection and analysis technology into the next generation of Nihon Kohden electrocardiographs.

• SonoSite (Bothell, Washington), which focuses on hand-carried ultrasound devices, said it has signed a distribution agreement for the veterinary market with Aloka Co. (Tokyo), a manufacturer and distributor of ultrasound systems. The agreement names Aloka as SonoSite’s non-exclusive veterinary distributor in the U.S. for SonoSite’s portfolio of hand-carried ultrasound systems through 2007.

No Comments